ArticleCureus2025
Midodrine and Weekly Albumin Therapy in Patients With Cirrhosis and Diuretic Intractable or Recurrent Ascites: A Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Perspectives on Long-Term Albumin Therapy in Decompensated Cirrhosis: A Nationwide Delphi Survey in Spain-The ALBA Study.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Overwhelming splanchnic and systemic vasodilatation and low mean arterial pressure (MAP) pose significant challenges in mobilizing ascites in patients with decompensated cirrhosis. We aimed to evaluate the efficacy and survival benefits of oral vasoconstrictor and weekly albumin therapy in patients with diuretic intractable and recurrent ascites in cirrhosis. Materials and methods A total of 113 cirrhotic patients with diuretic intractable (n=45) and recurrent ascites (n=68) with MAP ≤ 82 mmHg were included. Of the 113 patients, 85 patients received midodrine (12.5±2.5 mg thrice daily) and weekly albumin 20-40 g/day to achieve a serum albumin level of 4 g/dL with standard medical therapy (SMT), whereas 28 patients received SMT alone. On follow-up, at three months, we evaluated and compared the control of ascites, urinary sodium, systemic vascular resistance (SVR), and renal arterial resistive index (RARI) between arm 1 and arm 2. Results Among 113 patients, mean Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease-sodium (MELD-Na) scores were comparable in both arms (CTP 9.52±1.16 and 9±1.18 and MELD 21.33±4.17 and 22.36±4.2 in arm 1 and arm 2, respectively). After three months of therapy in arm 1, a significant increase was seen in urinary sodium excretion (25.99±15.73 and 114.38±71.33 meq/24 hours), MAP (78.91±3.11 and 84.3±3.13 mmHg), SVR (1,059.4±23.09 and 1,178.3±12.39 dynes/s/cm⁵), and decrease in RARI (0.71±0.054 and 0.67±0.039) (p <0.05). The median overall survival and ascites control were better in arm 1 (p <0.001) at the end of follow-up (12 months). Conclusion Response-guided midodrine and weekly albumin therapy, along with SMT, have better overall survival and ascites control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.